paraoxonase and arylesterase activities in patients with cancer

Authors

mohammad javad khodayar department of toxicology and pharmacology research center, school of pharmacy, jundishapur university of medical sciences, ahvaz, iran

mohammad seghatoleslami department of hematology-oncology, school of medicine, ahvaz jundishapur university of medical sciences, ahvaz, iran

maryam salehcheh department of medical laboratory sciences, para-medical faculty, ahvaz jundishapur university of medical sciences, ahvaz, iran

fatemeh jalali school of pharmacy, ahvaz jundishapur university of medical sciences, ahvaz, iran

abstract

background: cancer has the highest disease-related mortality rate in iran. reduced activity of paraoxonase reported in patients with cancer may be due to a reduction in its antioxidant properties and a subsequent increased risk of developing cancer. we aimed to assess antioxidant and oxidative status in patients with cancer through measuring the activity of pon1 as an antioxidant enzyme and determining mda as a marker of oxidative stress.  methods: this case-control study was conducted on 50 patients with colon, lung, blood or breast cancer and 50 age- and sex-matched healthy controls matching during 2014-2015. paraoxonase-1 and arylesterase activities were measured with paraoxon and phenylacetate substrates and their malondialdehyde levels and serum lipid profile were determined through spectrophotometry. results: serum paraoxonase activity was lower in patients with cancer (28.52±2.77 iu/l) compared with the healthy subjects (96.57±1.49 iu/l; p<0.0001). similarly, serum arylesterase activity was lower in patients with cancer (49.27±2.90) than the controls (66.91±2.47; p<0.0001). mda levels were higher in patients with cancer (1.3166±0.0876) than the healthy controls (0.9008±0.0452). the mann-whitney u-test showed significant differences between the two groups in terms of their triglyceride levels (p<0.05). although serum hdl levels were higher in the control group compared with the cases, the difference was not statistically significant (p>0.05). serum vldl, ldl and total cholesterol levels differed significantly between the two groups (p<0.05). conclusion: the results obtained showed a reduction in paraoxonase activity and an increased lipid oxidation in the patients with cancer and thereby reduced the antioxidant power of paraoxonase and weakened the body’s antioxidant system.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Paraoxonase and Arylesterase Activities in Patients with Cancer

Background: Cancer has the highest disease-related mortality rate in Iran. Reduced activity of paraoxonase reported in patients with cancer may be due to a reduction in its antioxidant properties and a subsequent increased risk of developing cancer. We aimed to assess antioxidant and oxidative status in patients with cancer through measuring the activity of PON1 as an antioxidant enzyme and det...

full text

Paraoxonase-1 and arylesterase activities in patients with colorectal cancer.

BACKGROUND The aim of this study was to evaluate paraoxonase-1 (PON1) and arylesterase (ARE) activities and oxidative stress status in patients with colorectal carcinomas (CRC). MATERIALS AND METHODS Thirty-three patients (20 male, 13 female) with CRC and 30 healthy controls were enrolled in the study. Blood samples were obtained from the CRC patients before adjuvant therapy. Serum samples fr...

full text

Paraoxonase and arylesterase activities in patients with preeclampsia.

OBJECTIVE Paraoxonase is a high density lipoprotein-associated anti-oxidant enzyme. The aim of this study was to investigate the serum paraoxonase and arylesterase activities and associations between these enzymes and lipid hydroperoxide (LOOH) in preeclamptic patients. MATERIALS AND METHODS The study included 47 preeclamptic (25 severe and 22 mild preeclampsia cases) and 20 normotensive heal...

full text

Serum paraoxonase and arylesterase activities in hemodialysis patients.

Cardiac death from atherosclerosis is common in hemodialysis patients. Human serum paraoxonase (PON1), an esterase, is associated with high-density lipoprotein and inhibits the susceptibility to oxidization of low-density lipoprotein (LDL). The PON1 genetic polymorphisms of 192 Gln/Arg and 55 Leu/Met in the amino acid sequence are partly involved in the PON1 enzyme activity. We investigated the...

full text

PARAOXONASE AND ARYLESTERASE ACTIVITY AMONG HYPERCHOLESTEROLEMIC PATIENTS

Human serum paraoxonase (PON) associated with high density lipoprotein (HDL) , has been postulated to have a role in protecting low-density lipoprotein (LDL) against oxidative damage, which has led to the proposal that PON is an anti-atherogenic and anti-inflammatory enzyme. It has genetic polymorphism at the 191 (R ->Q) and two alloenzymes A and B and three phenotypes A, B, and AB. We exa...

full text

Orginal Article Serum paraoxonase and arylesterase activities in patients with lung cancer in Turkish population

Background: Lung cancer (LC) is the leading cause of cancer death, and cigarette smoking is the most important cause. Oxidative DNA damage may contribute to the cancer risk. The high density lipoprotein (HDL) associated antioxidant paraoxonase (PON1) is an endogenous free radical scavenger in the human body. The aim of this study was to determine serum PON1 and arylesterase (ARE) activities in ...

full text

My Resources

Save resource for easier access later


Journal title:
iranian journal of blood and cancer

جلد ۹، شماره ۱، صفحات ۵-۱۱

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023